Nalaganje...
BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
The B-cell receptor (BCR) signaling inhibitors ibrutinib and idelalisib are revolutionizing the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies. These oral agents, both alone and in combination with other drugs, have shown remarkable clinical activity in relapsed or ref...
Shranjeno v:
| izdano v: | Mediterr J Hematol Infect Dis |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Università Cattolica del Sacro Cuore
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4771137/ https://ncbi.nlm.nih.gov/pubmed/26977270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2016.011 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|